KYMERA THERAPEUTICS, INC. Increase (Decrease) in Contract with Customer, Liability
KYMERA THERAPEUTICS, INC. (KYMR) reported Increase (Decrease) in Contract with Customer, Liability of -$34.37 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- KYMERA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$34.37M.
- KYMERA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$2.87M.
- KYMERA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$2.76M.
- KYMERA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was $20.79M.
- KYMERA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was -$41.08M.
- KYMERA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was -$8.61M.
- KYMERA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was -$37.77M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$34.37M 10-Q · filed 2026-08-05 | -$37.24M derived: sum of 3 quarters · filed 2026-08-05 | -$40.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$34.37M 10-Q · filed 2026-04-30 | -$37.24M derived: sum of 2 quarters · filed 2026-04-30 | -$40.00M derived: sum of 3 quarters · filed 2026-04-30 | -$11.48M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$2.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$5.63M derived: sum of 2 quarters · filed 2026-02-26 | $22.89M derived: sum of 3 quarters · filed 2026-08-05 | $20.79M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$2.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $25.76M derived: sum of 2 quarters · filed 2026-08-05 | $23.66M 10-Q · filed 2025-11-04 | $17.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $28.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $26.42M 10-Q · filed 2026-08-05 | $19.98M derived: sum of 3 quarters · filed 2026-08-05 | $17.55M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$2.10M 10-Q · filed 2026-04-30 | -$8.55M derived: sum of 2 quarters · filed 2026-04-30 | -$10.97M derived: sum of 3 quarters · filed 2026-04-30 | -$34.92M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$6.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$8.87M derived: sum of 2 quarters · filed 2026-02-26 | -$32.82M derived: sum of 3 quarters · filed 2026-02-26 | -$41.08M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$2.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$26.37M derived: sum of 2 quarters · filed 2025-11-04 | -$34.63M 10-Q · filed 2025-11-04 | -$23.75M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$23.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$32.20M 10-Q · filed 2025-08-11 | -$21.32M derived: sum of 3 quarters · filed 2026-02-26 | -$22.27M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$8.26M 10-Q · filed 2025-05-09 | $2.62M derived: sum of 2 quarters · filed 2026-02-26 | $1.67M derived: sum of 3 quarters · filed 2026-02-26 | -$10.72M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $10.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.93M derived: sum of 2 quarters · filed 2026-02-26 | -$2.46M derived: sum of 3 quarters · filed 2026-02-26 | -$8.61M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$950.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$13.34M derived: sum of 2 quarters · filed 2024-10-31 | -$19.49M 10-Q · filed 2024-10-31 | -$33.09M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$12.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$18.54M 10-Q · filed 2024-08-07 | -$32.14M derived: sum of 3 quarters · filed 2025-02-27 | -$38.81M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$6.14M 10-Q · filed 2024-05-02 | -$19.75M derived: sum of 2 quarters · filed 2025-02-27 | -$26.42M derived: sum of 3 quarters · filed 2025-02-27 | -$35.56M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$13.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$20.27M derived: sum of 2 quarters · filed 2025-02-27 | -$29.41M derived: sum of 3 quarters · filed 2025-02-27 | -$37.77M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$6.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$15.81M derived: sum of 2 quarters · filed 2023-11-02 | -$24.17M 10-Q · filed 2023-11-02 | -$39.31M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$9.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$17.50M 10-Q · filed 2023-08-03 | -$32.64M derived: sum of 3 quarters · filed 2024-02-22 | -$51.40M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$8.36M 10-Q · filed 2023-05-04 | -$23.50M derived: sum of 2 quarters · filed 2024-02-22 | -$42.26M derived: sum of 3 quarters · filed 2024-02-22 | -$59.89M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$15.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$33.90M derived: sum of 2 quarters · filed 2024-02-22 | -$51.53M derived: sum of 3 quarters · filed 2024-02-22 | -$69.36M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$18.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$36.40M derived: sum of 2 quarters · filed 2022-11-03 | -$54.22M 10-Q · filed 2022-11-03 | -$66.14M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$17.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$35.45M 10-Q · filed 2022-08-09 | -$47.38M derived: sum of 3 quarters · filed 2023-02-23 | $88.66M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$17.82M 10-Q · filed 2022-05-03 | -$29.75M derived: sum of 2 quarters · filed 2023-02-23 | $106.29M derived: sum of 3 quarters · filed 2023-02-23 | $103.01M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$11.93M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $124.12M derived: sum of 2 quarters · filed 2023-02-23 | $120.83M derived: sum of 3 quarters · filed 2023-02-23 | $117.40M 10-K · filed 2023-02-23 |
| 2020-09-30 | $136.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $132.76M derived: sum of 2 quarters · filed 2021-11-10 | $129.33M 10-Q · filed 2021-11-10 | $127.49M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$3.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | -$6.72M 10-Q · filed 2021-08-06 | -$8.55M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2020-03-31 | -$3.43M 10-Q · filed 2021-05-06 | -$5.26M derived: sum of 2 quarters · filed 2022-02-24 | ||
| 2019-12-31 | -$1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $52.99M 10-K · filed 2022-02-24 | ||
| 2019-09-30 | $54.83M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |